Transplant coronary artery disease: Incidence, progression and interventional revascularization

Bonni Syeda1, Suzanne Roedler, Christoph Schukro

  • 1Division of Cardiology, Department for Internal Medicine II, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. bonni.syeda@meduniwien.ac.at

Insights

Allograft coronary artery disease (CAD) incidence increases significantly after five years post-heart transplant. Coronary intervention offers better long-term outcomes for significant stenosis compared to conservative management.

Area of Science:

  • Cardiology
  • Transplant Medicine
  • Vascular Biology

Background:

  • Allograft coronary artery disease (CAD) is a primary cause of late graft loss after heart transplantation.
  • Understanding CAD incidence and progression is crucial for improving long-term transplant outcomes.

Purpose of the Study:

  • To analyze the incidence and progression of allograft CAD in heart transplant recipients.
  • To evaluate the effectiveness of coronary interventions for CAD in this patient population.

Main Methods:

  • Prospective analysis of angiographic data from heart transplant patients undergoing coronary angiography.
  • Assessment of angiographic outcomes following coronary revascularization for de novo lesions.

Main Results:

  • 30.9% of patients showed CAD (%DS>50%), with 19.5% having significant stenosis (%DS>70%).
  • CAD incidence rises exponentially after 5 years, with 50% developing CAD by 10.1 years.
  • Coronary intervention in 28 vessels showed a 25.9% binary restenosis rate, but offered better long-term results than conservative treatment for %DS>70% lesions (p=0.04).

Conclusions:

  • Allograft CAD incidence accelerates significantly beyond 5 years post-transplant.
  • Coronary interventions demonstrate comparable restenosis rates to other high-risk patients.
  • Interventional treatment for significant stenosis (%DS>70%) yields superior mid-term outcomes compared to conservative management.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...